Opthea Limited (ASX:OPT)
Share Price and News
Opthea Limited (ASX:OPT) is a biologics drug developer focusing on the therapies related to ophthalmic diseases. The group is having intellectual property protection around few Vascular Endothelial Growth Factors, namely, (VEGF)-C, VEGF-D and VEGFR-3; and Vegenics Pty Ltd., the subsidiary of Opthea holds the intellectual property rights. The technology under discussion, VEGF can regulate the blood as well as lymphatic vessel growth; and Opthea is focusing on developing its key product, OPT-302 (VGX-300, soluble VEGFR-3) that can cure wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are known to be related to eye diseases.